SIM0500
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 130 patients (estimated)
- Sponsors
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Collaborators
- Shanghai Xianxiang Medical Technology Co., Ltd.
- Tags
- Trispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2022
- NCT Identifier
- NCT06375044
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.